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There is abundant evidence of the important role of basic research in driving innovation, 
economic growth and welfare (Mansfield, 1980; Jaffe, 1989; Griliches, 1986; Adams, 1990; 
Salter and Martin, 2001). Basic research can be defined as activities that are directed towards the 
general advancement of men’s knowledge about the physical world, but without specific 
commercial objectives (Nelson, 1959). These activities expand the knowledge base available for 
firms on which they can draw in their technological activities (Klevorick et al, 1995). Numerous 
important technical inventions were the direct result of advances in scientific knowledge 
resulting from basic research.1 To what extent it is rational for firms to be involved themselves in 
basic research has been subject to a long debate among economists. Nelson (1959) argues that 
firms are reluctant to invest in basic research due to high degrees of uncertainty, long time 
frames to bear fruit, and appropriability problems. Appropriability problems result from the fact 
that the outcome of basic research, i.e. knowledge, is believed to be (at least partly) a public 
good and therefore freely available to other firms, including those that did not invest in basic 
research themselves (Arrow, 1962). Rosenberg (1990), on the other hand, argues that, despite 
these difficulties, there are rational reasons for private firms to conduct internal basic research 
activities. Firms that perform basic research may, for example, benefit from first-mover 
advantages, and improve the efficiency of their technology activities by developing a deeper 
understanding of the phenomena under study. In addition, internal basic research capabilities will 
help firms to develop the absorptive capacity (Cohen and Levinthal, 1990) to monitor, interpret, 
appraise, and utilize findings emanating from basic research conducted outside the firm.  
 
A small number of empirical studies have examined the impact of basic research on the 
technological performance of firms, providing mixed results. These studies focused either on the 
role of internal basic research, or on the effect of the usage of external basic research findings. 
Among the first studies, Gambardella (1992) found that US pharmaceutical firms with stronger 
in-house basic research skills produced a greater number of inventions. Cockburn and Henderson 
(1998) found positive effects of internal basic research only when this research was undertaken 
                                                          
1 A famous example is the development of the transistor at the Bell Telephone Laboratories in 1948 as a result of 
basic research activities of company scientists on the workings of semiconductor materials (Nelson, 1962).  
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in collaboration with university scientists. Lim (2004) found no effect of internal basic research 
on the patenting performance of pharmaceutical firms, while a counterintuitive negative effect 
was found for semiconductor firms.2 Using a sample of pharmaceutical and biotechnology firms, 
Fabrizio (2009) found that firms that conduct more basic research tend to produce inventions 
(patents) of higher value. A second set of studies examined the effect of the exploitation of 
external basic research findings (measured by citations to scientific literature in firm patents) on 
the value of firm inventions (forward citations of patents). Fleming and Sorenson (2004) 
identified a positive relationship between patent value and citations to scientific literature in 
fields where technology development is complex. For a sample of Belgian firms, Cassiman et al 
(2008) similarly found qualified support for the effect of external basic research on firm 
innovation. While they did not find a direct relationship between  the presence of scientific 
references on patent documents and patent value, results were indicative that exploiting external 
basic research did increase the value of firms’ other patents, in particular when firms were also 
active in establishing broader linkages with scientific research.  
 
This paper extends and improves on this body of prior empirical work on the importance of basic 
research for firms’ innovative performance. Our study is the first to jointly examine the impact of 
self-performed basic research (internal basic research) and the usage of external basic research 
findings in firms’ technology activities (external basic research) on firms’ technological 
performance. This allows us to explicitly test for potential complementarities between both types 
of basic research activities. In particular, we test whether firms with stronger internal basic 
research capabilities are better positioned to benefit from the usage of external basic research 
findings in their technology development activities. Second, we use more accurate indicators for 
basic research than prior empirical work. Prior studies have predominantly used the number of 
corporate scientific articles as proxy for internal basic research activities, and references to 
scientific articles in firm patents as proxy for the exploitation of external basic research findings 
in firms’ technology activities. However, scientific articles are an imperfect measure of basic 
research because a large share of these articles report on applied research activities related to 
clinical trials (Hicks, 1994). Using information on the specific journals in which firms’ scientific 
                                                          
2 While the study of Lim (2004) makes a distinction between firms’ publications in basic and applied research 
journals, his analysis of the relationship between firms’ patent performance and publication activities did not control 
for difference in firm R&D inputs, which may partly explain the heterogeneity in the empirical results. 
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articles are published and the CHI classification scheme for basic versus applied research 
(Hamilton, 2003), we construct more accurate indicators of internal basic research and the 
exploitation of external basic research by relying on the subset of corporate scientific articles 
appearing in journals that are classified as dealing with basic research.   
 
Our study uses panel data (1995-2002) on the patent and publication activities of 33 of the 
world’s largest R&D spending pharmaceutical firms. Applying fixed effects models and 
controlling for R&D inputs and past innovative performance, we find that firms engaging in 
internal basic research increase their technological performance, in particular when these 
activities are undertaken in collaboration with universities. In addition, we observe that firms can 
improve their technological performance by more frequently exploiting external basic research 
findings in their technology activities. The impact of the exploitation of external basic research 
on firms’ performance increases when firms do more internal basic research, confirming that 
internal basic research and the exploitation of external basic research are complements. 
 
The remainder of the paper is organized as follows. The next section provides a brief overview 
of the existing literature on the relationship between basic research and innovation and describes 
the research priors. We proceed with a description of the data and the empirical model in section 
three. The empirical results are discussed in section four and in the final section, we conclude on 
the main findings and suggest avenues for further research. 
 
 
2. Private Firms and Basic Research 
 
Background 
Basic research has received many definitions (Rosenberg, 1990). We adopted the definition of 
the National Science Foundation (NSF) where basic research is defined as the systematic study 
directed towards greater knowledge or understanding of the fundamental aspects of phenomena 
and observable facts without specific immediate commercial applications in mind, although 
research may be in fields of present or potential commercial interest of those performing the 
research activities (NSF, 2009). Applied to the pharmaceutical industry, basic research includes 
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attempts to reveal the mechanisms and processes of diseases, but does not include applied 
research activities such as compound screening, clinical trials and dosage testing (Lim, 2004). 
Basic research activities conducted by firms are concentrated in two different respects. First, the 
majority of basic research is conducted in a small number of industries such as pharmaceuticals, 
chemicals, electrical machinery and aerospace (Mansfield, 1980; Rosenberg, 1990). These 
sectors are called ‘science-based industries’ in Pavitt’s (1984) classical sector taxonomy.  
Second, within these sectors a handful of firms perform a large share of the basic research 
activities. These firms are typically large firms with diverse product and technology portfolios 
and large R&D laboratories. These firms are more confident that they will be able to put both 
anticipated and unexpected findings from basic research into commercial use (Nelson, 1959).  
 
Basic research is a process of learning of the physical world that generates knowledge which is 
available for firms to draw upon in their applied technology activities (Klevorick et al, 1995; 
Matutes et al, 1996). Mansfield (1995 & 1998) examined the importance of basic research for 
firms’ technology activities by surveying samples of US firms across different industries. He 
found that, during the period 1975-1985, 11% of firms’ new products and 9% of new processes 
could not have been developed (or with substantial delay) in the absence of basic research 
conducted by universities. These numbers are higher for the period 1986-1994 (respectively 15% 
and 11%), suggesting that basic research findings increase their importance for industrial R&D. 
Another indication of the growing reliance of industrial technology activities on (basic) scientific 
knowledge can be found in the analysis of citations to scientific literature in patent documents. 
For instance, Narin et al (1997) reported a threefold increase in the number of citations to 
scientific literature in industrial patents in the United States during the early and mid 1990s.  
 
Basic Research in the Pharmaceutical Industry 
Basic research is an important source of knowledge for industrial innovation in many industries, 
but particularly in the pharmaceutical industry (McMillan et al, 2000). Patents in drugs and 
medicine classes cite significantly more scientific articles than patents in other classes (Narin et 
al, 1997) and cite basic scientific research more heavily (Narin and Olivastro, 1992). The strong 
reliance of pharmaceutical firms on basic research becomes also apparent from the case histories 
of the discovery of 21 important drugs described by Cockburn and Henderson (1998). 
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Fundamental insights in basic research played a role in the discovery of sixteen of these drugs. 
The link between basic research and drug discovery has increased over time (Lim, 2004). 
Pharmaceutical firms have moved away from randomly screening a large number of potentially 
useful compounds against a certain disease, towards a more systematic approach called rational 
drug design. This approach involves exploiting knowledge about the biochemical mechanisms 
causing a disease to identify and develop compounds that inhibit the mechanisms (Pisano, 1997).  
 
Basic research has become part of the drug discovery processes in most pharmaceutical firms. 
Based on case studies of US pharmaceutical firms, Gambardella (1992) has however shown that 
pharmaceutical firms pursue different strategies with respect to the importance given to basic 
research. For example, while Merck invested strongly in internal basic research and used this 
knowledge to exploit and further build on externally generated basic research findings, Bristol-
Myers on the other hand has had only modest internal basic research skills (Gambardella, 1992).  
 
Research Priors 
The purpose of the current study is to examine whether differences in internal and external basic 
research strategies of pharmaceutical firms translate in differences in technological performance, 
while examining the potential complementarity between internal and external basic research. 
Below we formulate a number of priors on these relationships. 
 
Exploitation of External Basic Research  
Company researchers often consult scientific literature to solve technical difficulties in their 
technology activities (Allen, 1977; Gibbons and Johnston, 1974). Organizations that frequently 
consult and exploit external basic research findings in their technology activities are expected to 
develop a deeper understanding of the fundamental principles of the phenomena under study 
(Rosenberg, 1990). Basic scientific knowledge allows firms to anticipate the results of research 
experiments without performing them, helping firms to prioritize research avenues and to avoid 
costly and time consuming research trials that lead to low-value outcomes (Fabrizio, 2009). In 
other words, basic scientific knowledge informs firms on the success probabilities of different 
directions to conduct applied research (Fleming and Sorenson, 2004; Cassiman et al. 2008). 
Basic scientific knowledge also helps firms to evaluate the outcomes of applied research and to 
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perceive its implications (Rosenberg, 1990). These arguments suggest that firms that exploit 
more external basic research findings in their technology activities may be able to increase their 
technological performance.  
 
Internal Basic Research 
Firms that conduct internal basic research benefit from the scientific knowledge that is generated 
by these research activities in a similar way as firms that exploit external basic research findings. 
Basic scientific knowledge serves as a map of the technological landscape which firms search for 
inventions, guiding them towards the most promising research directions (Fleming and Sorenson, 
2004). Performing in-house basic research has however additional advantages for firms’ 
technological performance. First, internal basic research capabilities may act as an admission 
ticket to R&D partnering with universities and public research organizations (Liebeskind et al, 
1996; Cockburn and Henderson, 1998). Internally performed basic research activities 
demonstrate the scientific competences firms need in order to enter into relationships of 
information exchange with public sector scientists (Hicks, 1994).  Second, internal basic research 
may act as a powerful recruiting tool, since the scarce highest quality researchers (‘stars’) are 
reluctant to work for firms in which they are not allowed to do basic research and publish 
scientific findings (Henderson and Cockburn, 1994; Hicks, 1999; Narin & Breitzman, 1995). 
Publishing is one of the most important means for scientists to establish their reputations 
(Stephan, 1996) and corporate scientists are found to be willing to accept lower wages in 
exchange for the permission to conduct and publish scientific research (Stern, 2004). It has been 
shown that employing star scientists can have a large positive impact on the technological 
performance of firms (Zucker et al, 2002; Furukawa and Goto, 2006).  
 
Taken together, the arguments above suggest that firms can increase their technological 
performance by conducting internal basic research activities. There are reasons to believe that the 
benefits of internal basic research are larger when research activities are conducted in 
collaboration with universities. Collaboration with university scientists often leads to extensive 
debate, exchange of ideas and discussions. This provides firms with access to tacit knowledge of 
university scientists, which is not provided in journal articles (Arora and Gambardella, 1990; 
Cockburn and Henderson, 1998). Furthermore, these collaborations may help firms to get access 
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to relevant codified scientific research of university scientists that is not yet published, allowing 
firms to build faster on recent research findings in their own research activities (Fabrizio, 2009). 
Hence, firms that conduct a greater share of their internal basic research activities in 
collaboration with universities may be able to benefit most, in terms of technological 
performance, from internal basic research. 
 
Complementarity Between Internal Basic Research and External Basic Research 
External basic research findings are not a free input to firms’ own research activities (Rosenberg, 
1990). As Cohen and Levinthal (1990) have noted, learning is a cumulative, incremental process 
which is influenced by capabilities that are already present at the individual and organizational 
level. Individuals learn through a process whereby new events are stored in their memories by 
establishing linkages with pre-established concepts and ideas. An organization’s ability to learn 
depends, at least in part, on the ability of its individual members to learn as organizational 
learning involves the joint contribution of individual members to solve problems (Helfat, 1994). 
Therefore, the ability of organizations to learn from external research findings depends on the 
commonality between the organizations’ internal knowledge base and the external research 
findings which firms intend to exploit in their technology activities (Teece et al, 1997). Hence, 
firms that want to take advantage of research conducted outside their organizations need to invest 
in an ‘absorptive capacity’ in the sense of accumulating knowledge and skills to understand and 
utilize externally generated knowledge (Cassiman and Veugelers, 2006; Lokshin et al, 2008). 
The creation of an ‘absorptive’ capacity for external basic research findings, involves the 
employment of a cadre of scientists and granting them the freedom to perform basic research 
(Pavitt, 1991). Based on the absorptive capacity argument, firms with stronger in-house 
competences in basic research may be better equipped to benefit from the exploitation of external 
basic research findings in their own technology activities.  
 
 
3. Data and Empirical Model 
 
We constructed a panel dataset on the patent and publication activities of 33 large R&D spending 
firms in the pharmaceutical industry. The sample firms are selected as top R&D spenders in the 
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pharmaceutical industry from the ‘2004 EU Industrial R&D Investment Scoreboard’. This 
scoreboard lists the top 500 corporate investors in R&D whose parent is located in the EU, and 
the top 500 companies whose parent is located outside the EU (mainly US and Japan), based on 
corporate R&D expenditures in 2003. The sample firms have headquarters in the United States, 
Europe and Japan and are observed over a period of eight years (1995-2002). The sample 
includes pharmaceutical firms and three large biotechnology firms (Chiron, Amgen and Genzyme).3 
The R&D investments of the sample firms totaled 40.2 billion US dollars in 2002. The smallest 
company R&D budget in our sample amounts to 175 million (Sepracor) and the largest R&D 
budget reaches almost 6 billion US dollars (Pfizer). 
 
Our measure of the technological performance of the firms is based on patent data. There are 
numerous advantages of the use of patent indicators (Pavitt, 1985; Basberg, 1987; Griliches, 
1990): patents contain detailed information on the technological content, owners and prior art of 
patented inventions; patent data are objective in the sense that they have been processed and 
validated by patent examiners; and patent data are easily available from patent offices and cover 
long time series. Like any indicator, patent indicators are also subject to a number of drawbacks: 
not all inventions are patented and those that are patented vary in their technical and economical 
value (Trajtenberg, 1990; Lanjouw et al, 1998; Gambardella, 2008). The first problem can be 
addressed by limiting patent analyses to industries with high patent propensities and studying 
firm-level patent time series.4 The ‘value’ problem can be taken care of by weighting patent 
counts by the number of forward patent citations received by these patents (Trajtenberg, 1990; 
Harhoff et al, 1999; Hall et al, 2005). Both approaches are followed in this paper.  
 
Since company names in patent databases are not unified and patents may be applied for under 
names of subsidiaries or divisions of a parent firm, we collected patent data at the consolidated 
parent firm level. Therefore, we searched, for each parent firm, for patents under the name of the 
parent firm as well as all their majority-owned subsidiaries. For this purpose, yearly lists of 
companies’ subsidiaries included in corporate annual reports, yearly 10-K reports filed with the 
                                                          
3Arora et al (2009) showed that these older, large, biotech firms display strategic behavior and innovation 
performance similar to pharmaceutical firms. Removing the three biotech firms from the sample did not have a 
material impact on the empirical results.  
4 The majority of inventions in the pharmaceutical industry are patented (Arundel and Kabla, 1998; Campbell, 2005) 
and firm-specific patent application policies are likely to be relatively stable over time.  
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SEC in the US, and, for Japanese firms, information on foreign subsidiaries published by Toyo 
Keizai in the yearly ‘Directories of Japanese Overseas Investments’, were used. The 
consolidation was conducted on a yearly basis to take into account changes in the group structure 
of sample firms due to acquisitions, mergers, green-field investments and spin-offs. Acquisitions 
are considered part of a parent firm from the year the acquisition transaction has been completed. 
 
Patent data are taken from the European Patent Office (EPO). The technological performance of 
the sample firms (dependent variable) is measured as the number of EPO patent applications of a 
parent firm in a year, weighted by the number of forward patent citations received by those 
patents over a fixed time window of 4 years. The number of forward patent citations is calculated 
on a fixed time window because the number of forward citations to any patent depends on the 
length of the citation window (Hall et al, 2005; Trajtenberg, 1990). Forward patent citations are 
calculated on the EPO patent citation database described in Webb et al. (2005) and are calculated 
for all citing EPO patents and national patents with EPO patent equivalents.   
 
Internal Basic Research  
We used information on scientific publications authored by the sample firms and published in 
peer reviewed international journals to assess the internal basic research activities of firms. 
Publication data are extracted from yearly updates of the Science Citation Index database of 
ISI/Thomson Scientific; documents of the type article, letter, note and review have been selected.  
Publication data is collected at the consolidated parent firm level, following a similar approach 
as the one followed for the collection of patent data. This approach consists of identifying all 
publications on which the parent firms, or their subsidiaries, are listed as publishing institutes. 
The consolidation exercise is conducted annually. In line with studies of Hicks et al (1994) and 
Cockburn and Henderson (1998) we find that pharmaceutical firms publish extensively; the 
sample firms published on average 263 publications per year in the SCI database over the period 
1995-2002. We collected bibliographic information (journal name, volume, pages etc.) for all the 
publications on which the 33 sample firms are listed as one of the authors’ institutions.  
 
We classified a publication as ‘basic research’ based on the journal in which it is published and 
the CHI journal classification scheme which classifies each of the SCI journals in one of four 
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research levels, in a spectrum ranging from very applied, targeted research to basic research. For 
biomedical journals the four different research levels are called ‘clinical observation’ (level 1), 
‘clinical mix’ (level 2), ‘clinical investigation’ (level 3) and ‘basic biomedical research’ (level 
4)5. Journals that are classified in level 4 are considered as reporting mainly basic research 
findings. About 36% of the SCI publications of the sample firms are published in basic research 
journals. The remaining 64% of SCI publications report on applied research activities of the 
sample firms (clinical trials) and are not used in the construction of the internal basic research 
variables.  
 
The internal basic research variable is constructed on the basis of a 4-year moving time window. 
The internal basic research expertise of a firm in year t is measured as the sum of firm 
publications that are published in basic research journals in the past 4 years (t-4 to t-1) by firm 
subsidiaries that were part of the parent firm in year t. The variable is divided by the size of the 
firm’s R&D expenditures in year t-1 to make it independent of the scale of the firm’s R&D 
activities, in line with prior work of Cockburn and Henderson (1998) and Fabrizio (2009). 
 
Following prior work by Cockburn and Henderson (1998) and Fabrizio (2009), the intensity of 
collaboration between the firm and university scientists in basic research is measured as the share 
of firm publications in basic research journals that are co-authored with universities. To identify 
firm publications that are jointly written with university scientists we coded the presence of the 
words university, college or regents in the publishing institutes names of firms’ publications. 
 
Exploitation of External Basic Research 
Our measure of the exploitation of external basic research findings in firms’ technology activities 
is based on references in the prior art of firms’ patents to publications in basic research journals 
(not published by the firm itself). The prior art section of a patent contains references to prior 
patents and non-patent literature, including scientific articles. The legal purpose of the references 
is to indicate which parts of the knowledge described can be claimed by the patent and which 
parts have been claimed by other patents and non-patents. Patent references restrict the scope of 
                                                          
5 An example of a journal that is classified in level 1 is the Journal of the American Medical Association. The 
Journal of Biological Chemistry is an example of a journal that is classified in level 4 (Hamilton, 2003). 
12 
 
patent claims to novelty and represent a link to the pre-existing knowledge base upon which 
patents have been built (Criscuolo and Verspagen, 2008; Jaffe et al, 2004). This feature has been 
used by prior studies (e.g. Narin et al, 1997; Fleming and Sorenson, 2004) to justify the use of 
patent references as information source on the knowledge base of patent applicants.  
 
One critique to this particular use of patent references is that the prior art section of patents 
includes references provided by patent applicants while filing their patents as well as references 
added later on by patent examiners during their search for relevant prior art (Alcacer and 
Gittelman, 2006). The problem is that patent applicants may not know part of the references 
cited in the prior art of their patents, especially references made by patent examiners (Brusoni et 
al, 2005). However, surveys of USPTO patent inventors (Jaffe et al, 2004; Fleming and 
Sorenson, 2004; Tijssen et al, 2000) have shown that inventors are aware of a significant part of 
the patents and scientific articles that are cited in the prior art of their patents, including some of 
the references made by patent examiners6. Using data on EPO patents and responses to the 
Community Innovation Survey (CIS) for a sample of French firms, Duguet and MacGarvie 
(2005) find a positive correlation between the number of references in firms’ patents and the 
intensity to which firms have sourced external knowledge. We consider this sufficient evidence 
to take scientific references on patents as an (although imperfect) indicator of the knowledge 
base that firms have drawn on, or at least had an awareness of, in their technology activities.  
 
Non-patent references were extracted for all EPO patents of the sample firms, using information 
from the patents’ search reports. Patents cite a variety of non-patent references, such as scientific 
articles, books, newspapers, company reports and industry related documents, which do not all 
refer to basic research findings  (Harhoff et al, 2003; Callaert et al, 2006). We have used non-
patent references to scientific articles in basic research journals in the calculation of our firm-
level indicator of the usage of external basic research. These references are identified via a text-
                                                          
6 In a survey of USPTO patent inventors, Jaffe et al (2004) find that patent inventors have a moderate to high 
familiarity with more than 50% of the cited patent references. Given that, on average, 63% of patent references in 
USPTO patents are provided by patent examiners (Alcacer and Gittelman, 2006), this shows that patent applicants 
are also aware of part of the patent references that are added by patent examiners. Among all references on patents, 
references to scientific articles are more frequently added by patent applicants themselves (Narin and Noma, 1985; 
Jaffe et al, 1998), which explains a much higher degree of familiarity of patent inventors with scientific articles cited 
on their patent documents: Fleming and Sorenson (2004) and Tijssen et al (2000) report that patent inventors are 
aware of 62% and 84% of the cited articles in their patents, in their respective surveys.  
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matching algorithm and the CHI list of all research journals (applied/basic) in the SCI database. 
Specifically, non-patent references (NPRs) to scientific articles in the SCI database are identified by 
checking for the presence of SCI journal names (6,400 journals) in the text strings of the NPRs on the 
patent documents. Patents of our sample firms cited on average 1,62 non-patent references in their 
prior art section. About 70% of these non-patent references referred to publications in scientific 
journals (SCI database); 40% of these non-patent references referred to publications in basic 
research scientific journals. These numbers are comparable with numbers found in prior studies 
on the nature of non-patent references (Harhoff et al., 2003; Callaert et al., 2006). 
 
Since we want to measure the exploitation of external basic research findings in firms’ R&D 
activities, references to basic research publications authored by the firm itself have to be 
removed from our indicator. On average, 7% of the citations to publications in basic research 
journals referred to publications of the citing firm. We identified NPRs to publications of the 
firm itself by retrieving (for all scientific NPRs) information on the volume, year and starting 
page of the publication to which the NPRs refer. An NPR was considered to refer to a 
publication of the firm itself when the journal name, volume, year and starting page in the NPR 
text were identical to one of the publications identified as authored by the firm.  
 
In parallel with the internal basic research variable, our measure of the exploitation of external 
basic research findings in firms’ technology activities is also computed on a 4 year moving 
window. More specifically, the exploitation of external basic research variable is calculated as 
the average number of citations to publications in basic research journals (not belonging to the 
firm itself) in patents that are applied for by the firm (subsidiaries of the firm in year t) in the past 
4 years (t-4 to t-1). The variable is expressed as an intensity to make it independent of the scale 
of firms’ technology activities for which the analysis controls separately. 
 
Control Variables 
Our empirical models control for other (time varying) firm-level factors that are likely to impact 
on firms’ technological performance. First, we control for differences in the scale of the firms’ 
R&D expenditures, taking a one-year time lag between R&D expenditures and firm patents. The 
data on firms’ R&D expenditures are collected from corporate annual financial reports 
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(Worldscope and Compustat databases) and are measured in millions of US dollars. Second, we 
control for differences in the prior patent productivity of firms, measured as the one-year lagged 
ratio of the number of firm patents to R&D expenditures. Third, we include an indicator for the 
level of technology diversification in a firm’s patent portfolio such that both scale and scope of 
R&D activities of firms are controlled for (Arora et al, 2009, Henderson and Cockburn, 1996; 
Nesta and Saviotti, 2005). Technology diversification is measured as the ‘spread’ of patents in a 
firm’s 4-year patent portfolio over technology classes. Technology class information on patents 
is derived from the IPC classes assigned to patents. We distinguished between 120 different 3-
digit IPC classes to construct the diversification measure. The technology diversification variable 
is the inverse of the so-called Herfindahl index: it takes higher values when the level of 
technology diversification increases. Both linear and quadratic terms of technology 
diversification are included in the regression model to test for the existence of an inverted U-
shape relationship between technology diversification and firm technological performance (e.g. 
Henderson and Cockburn, 1996; Leten et al, 2007). Finally, the empirical models include time 
dummies (1995 as base category) to account for time-specific factors affecting the technological 
performance (forward citation weighted patent numbers) of the sample firms.  
 
Methods 
The dependent variable (citation-weighted patent count) is a count variable with only non-
negative integer values. In this case, nonlinear count data models are preferred to standard linear 
regression models as they explicitly take into account the non-negativity and discreteness of the 
dependent variable. Negative Binomial count data models, which control for over-dispersion in 
the dependent variable, are used (Cameron and Trivedi, 1998). We have used fixed effects panel 
data estimators in all regression models to control for unobserved (time-invariant) firm 
characteristics; such as R&D management capabilities, that could affect technological 
performance. Besides including fixed-effects, our empirical specification has other features that 
alleviate concerns of potential endogeneity and biases stemming from unobserved factors. First, 
the temporal ordering of the variables in the model - where past publication and NPR counts are included 
to explain current performance – avoids reverse causality where higher innovation performance and the 
ensuing higher availability of R&D resources may lead to more internal basic research and more frequent 
exploitation of external basic research. Second, we include several key time-varying firm characteristics 
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as control variables (R&D expenses, patent intensity, and technology diversification) that are likely to 
pick up time variant firm traits such as developments in corporate R&D resources and capabilities. 
 
Summary Statistics 
Summary statistics of the dependent and explanatory variables can be found in Table 1. There is 
substantial variation between the sample firms in the internal and external basic research 
variable, with maximum values being several times larger than the minimum and mean values. 
The sample firms do actively collaborate with universities in internal basic research activities; 
the percentage of internal basic research publications that are co-authored with universities is on 




Insert Table 1 about here 
------------------------------ 
 
Table 2 reports the coefficients of correlation between the variables of interest. As to be 
expected, the correlation between technology diversification and its squared term is considerable; 
none of the other reported correlations is excessively high. There is a positive correlation 
between internal and external basic research. This suggests that firms which conduct more 
internal basic research do more actively exploit external basic research findings in their 
technology activities, providing first evidence of the complementary character of both activities.  
 
------------------------------ 
Insert Table 2 about here 
------------------------------ 
 
Figure 1 shows the internal and external basic research activities for the sample firms, measured 
as the firm’s average number of publications per year and the firm’s average number of NPRs per year, 
respectively. While the positive correlation between the two types of basic research is apparent, 
the figure also illustrates that the firms are heterogeneous in their focus on internal versus 
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external basic research. For example, whilst both companies on average make a comparable 
number of citations to external basic research in their patents (about 130), the research strategy 
of Novartis places relatively more emphasis on internally performed basic research than Bristol-
Myers Squibb in terms of publications in basic research journals (630 versus 340).  
 
------------------------------ 
Insert Figure 1  about here 
------------------------------- 
 
Finally, Figure 2 shows the evolution in internal and external basic research activities over the 
sample period. The average basic research publication activity across firms has remained roughly 
constant.7 Turning to the citations to (non-firm) basic research publications on firm patents, there 
is a clear increasing trend, in line with the findings of Narin et al. (1997).  
 
------------------------------ 




4. Empirical Results 
 
The empirical results of the fixed effects Negative Binomial regression models of the 
relationship between internal basic research, the exploitation of external basic research findings 
and the technological performance of firms are reported in Table 3. Model 1 includes only the 
control variables and acts as point of comparison for the other models. The R&D expenditures 
and patent intensity variables have the expected positive signs and are both statistically 
significant. Technology diversification has a positive linear term, and a negative quadratic term. 
The linear term is significant in all models; the quadratic term is only significant in the most 
complete model 5. These results confirm the existence of an inverted U-shape relationship 
                                                          
7 By comparison, Gambardella (1992) reported figures on the whole of basic and applied publications by a small 
number of US pharmaceutical firms in the period 1973-1986. He observed a significant upward trend for some firms 
(e.g. Merck), but not for all (e.g. Eli Lilly). 
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between technology diversification and firms’ technological performance. The peak of the 
inverted U-shaped curve occurs at a value of 4,78 (calculation done for model 5), with 19% of 
the sample firms having larger values for the technology diversification variable.   
 
------------------------------ 
Insert Table 3 about here 
------------------------------ 
 
The external basic research variable is positive and significant in model 2, showing that firms 
can increase their technological performance by exploiting more external basic research findings 
in their technology activities. When the internal basic research variable is added to the model 
(model 3), its coefficient is positive and significant, while the coefficients of the other variables 
do not change materially. This confirms that internal basic research has a positive impact on 
firms’ technological performance. The magnitude of the impact of internal and external basic 
research on firms’ technological performance can be derived directly from the estimated 
coefficients of both basic research variables, which can be interpreted as semi-elasticities. Both 
variables have a similar semi-elasticity: a one-unit change in basic research (which implies 
roughly 2 standard deviations change) increases firm performance by 33 percent.  The coefficient 
of the variable ‘collaboration with universities in internal basic research’ is positive and 
significant coefficient when added (model 4), which implies that internal basic research has a 
larger positive impact on firms’ technological performance when it is conducted in collaboration 
with universities.  
 
In the final model (model 5), the interaction effect between internal basic research and the 
exploitation of external basic research is added to the analysis.8 The coefficient of the interaction 
variable is positive and significant, while the coefficients of both main effects also remain 
positive and significant. In non-linear regression models such as the Negative Binomial model, 
the sign and significance of the interaction variable is however no definitive indication of the 
sign and significance of the interaction effect (Hoetker, 2007). The interaction effect, in which 
                                                          
8 The interaction effect is created as the product of the demeaned values of internal basic research and the 
exploitation of external basic research. This approach allows evaluating the main effects of both basic research 
variables at ‘meaningful’ values (mean value of the other basic research variable) rather than at the level zero. 
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we are interested, is calculated as the partial cross-derivative of the conditional mean function of 
the fixed effect Negative Binomial model with respect to both variables (internal basic research 
and usage of external basic research). We calculated the value of the cross-derivative function 
for all sample observations. The coefficient for the cross-derivate took positive values for all 245 
sample observations and was significant at 10% level for 244 of the 245 observations. These 
results provide strong support for the notion of a complementary relationship between internal 
basic research and the exploitation of external basic research findings. 
 
One way to illustrate the magnitude of the complementary effects of internal and external basic 
research on firm technological performance is to depict the value of the predicted citation-
weighted patents (on the vertical axis) for different combinations of internal and external basic 
research (Figure 3; the other regressors are taken at their sample means). The values for internal 
and external basic research vary within one standard deviation from their mean. The surface plot 
in Figure 3 confirms the main effects of internal and external basic research, and more 
importantly, illustrates the magnitude of the interaction effect of both variables. Clearly, it is the 
joint increase in internal and external basic research that has the dominant influence on firms’ 
technological performance. For firms with a low internal basic research capability, an increase of 
the usage of external basic research from low to high values increases the firm’s technological 
performance (patent output) by 7 percent (from 75 to 80); while for firms with a strong internal 
research capability patent output increases by 78 percent (from 99 to 176). These observations 
clearly illustrate the importance of pursuing internal basic research activities and the sourcing of 
external basic research findings simultaneously. These results, in combination with the 
heterogeneous basic research strategies adopted by firms (Figure 1) and the rise in the 
exploitation of external basic research without a commensurate increase in internal basic 
research (Figure 2), may suggest that there are firms that could increase their performance by 
developing stronger internal basic research capabilities. In addition to a direct positive effect on 
technological performance, this would increase the return of the usage of external basic research. 
 
-------------------------------- 






This paper examined the effects of basic research on the technological performance of firms in 
the pharmaceutical industry. We extended prior studies by jointly examining the impact of basic 
research performed by the firms in-house (internal basic research) and the usage of external basic 
research findings in firms’ R&D activities (exploitation of basic research performed elsewhere). 
We explicitly tested for the potentially complementary character of both types of basic research 
activities. We analyzed the effects of firms’ basic research strategies drawing on a panel dataset 
(1995-2002) on the R&D, patent and publication activities of 33 large American, European and 
Japanese firms in the pharmaceutical industry. Internal basic research activities are measured by 
publications in basic research journals in which the firm or its subsidiaries are listed as the host 
institution of the authors. The exploitation of external basic research findings in firms’ 
technology activities is captured by references to web of science publications in basic research 
journals (excluding references to firms’ own publications) in the prior art of firms’ patents,  
 
Fixed-effects panel data analyses confirmed that engagement in internal basic research activities 
improves technological performance, in particular when these research activities are undertaken 
in close collaboration with universities. This finding is consistent with the ‘connectedness’ idea 
put forward in Cockburn and Henderson (1998), which states that research collaboration with 
university scientists offers opportunities for intense debate, discussion, and exchange of valuable 
tacit knowledge, which can improve the quality and impact of firms’ R&D activities. In addition, 
we find clear evidence that firms can increase their technological performance by more actively 
exploiting external basic research findings in their technology activities. The magnitude of the 
effect of external basic research exploitation is significantly greater if firms conduct more 
internal basic research. Hence, internal basic research activities and the exploitation of external 
basic research findings are complementary R&D strategies for firms. This complementarity is 
the dominant influence in the basic research – technological performance relationship, with the 
predicted effect of external basic research more than 10 times larger for firms with the strongest 
internal research capabilities as compared to firms with little internal basic research. These 
results, against the background of heterogeneous basic research strategies adopted by firms and 
the observed rise in the exploitation of external basic research without a commensurate increase 
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in internal basic research, suggest that there are pharmaceutical firms that could increase their 
technological performance by developing stronger internal basic research capabilities.  
 
Our analysis shows that internal basic research has both direct and indirect positive effects on 
firms’ technological performance. Internally conducted basic research provides firms with a 
deeper understanding of the phenomena under research, which on the one hand improves the 
efficiency of their technology activities, and on the other hand helps to monitor, interpret and 
utilize findings emanating from basic research that is conducted outside the firms. This indicates 
that external basic scientific knowledge is not a perfect public good and that firms need to invest 
in a sufficient ‘absorptive capacity’ to benefit fully from external basic research findings in their 
own technology activities. The observation that basic scientific knowledge is not freely available 
to all firms, but only to those who have the right background knowledge and skills, is consistent 
with Rosenberg’s (1990) perspective on the economics of basic research. Building up and 
maintaining this ‘absorptive capacity’ is however not easy or inexpensive to accomplish. It has 
major organizational consequences, as it involves hiring (top)-scientists and granting them the 
freedom to conduct basic research, preferably in collaboration with universities in the context of 
scarce firm R&D resources (Pavitt, 1991; Gambardella, 1992; Cockburn and Henderson, 1998).  
 
Our research had a number of limitations, which suggest fruitful directions for future research. 
Our findings on the role of basic research relate to firms in the pharmaceutical industry and one 
should be careful to generalize our findings to firms in other sectors. The pharmaceutical 
industry is exceptional with respect to the relevance of basic research for technology activities 
(McMillan et al, 2000; Rosenberg, 1990) and appropriability conditions due a high efficacy of 
patenting (Lim, 2004). However, we suspect that our results do have relevance to firms in other 
industries in which basic research and technology development are closely linked, such as 
semiconductors and electronics (Pavitt, 1984; Klevorick et al, 1995). The investigation of the 
relationship between basic research and firm performance in other industries is an interesting 
direction for further research. A second avenue for future research is examining more in detail 
the organizational characteristics of firms’ basic research activities. Rosenberg (1990) suggests 
that corporate basic research is likely sterile and unproductive if it is conducted in a separate unit 
isolated from the rest of the firm’s  R&D activities. The effectiveness of basic research is 
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expected to increase if it is conducted in close interaction with the work and interests of the 
firms’ engineers. One way to examine these interactions may be to analyze collaboration and 
citation patterns of corporate scientists and engineers, using, for example, information that is 
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N=245 Mean St. Dev. Min Max
Citation Weighted Patent Count 136.85 154.67 1 651
R&D Expenses (million $) 791.51 856.90 21.70 4847
Patent Intensity (patents per million $ R&D) 0.16 0.17 0.02 1.04
Technology Diversification 3.36 0.94 1.70 5.69
External Basic Research (NPRs per patent) 0.75 0.45 0.08 2.33
Internal Basic Research (publications per million $ R&D) 0.60 0.60 0.04 4.27
Fraction Internal Basic Research with Universities 0.46 0.12 0.11 0.78
N=245 1 2 3 4 5 6 7 8 9
1 Citation Weighted Patent Count 1
2 log (R&D Expenses) 0.63 1
3 Patent Intensity 0.12 -0.45 1
4 Technology Diversification 0.10 -0.07 0.47 1
5 Technology Diversification2 0.08 -0.10 0.48 0.99 1
6 External Basic Research -0.25 -0.21 -0.06 0.23 0.17 1
7 Internal Basic Research 0.26 -0.17 0.56 0.25 0.22 0.10 1
8 Share Internal BR with Universities -0.24 -0.17 0.08 0.18 0.17 0.25 -0.24 1
9 Internal BR * External BR -0.06 -0.06 -0.12 -0.10 -0.07 -0.17 -0.36 -0.01 1
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Table 3: Fixed Effect Negative Binomial Regression of the Effects of Internal  




Notes: Significance of coefficients is indicated by *(0.1), **(0.05) and ***(0.01). Standard errors are reported 








Model 1 Model 2 Model 3 Model 4 Model 5
Log (R&D Expenses) 0.23** 0.24** 0.29*** 0.32*** 0.38***
(0.11) (0.11) (0.10) (0.10) (0.10)
Patent Intensity 0.96** 1.05*** 0.79** 0.69* 0.70*
(0.38) (0.39) (0.40) (0.40) (0.40)
Technology Diversification 0.62* 0.61* 0.63* 0.62* 0.67**
(0.33) (0.34) (0.34) (0.34) (0.34)
Technology Diversification2 -0.06 -0.06 -0.06 -0.06 -0.07*
(0.04) (0.04) (0.04) (0.04) (0.04)
External Basic Research 0.33** 0.33** 0.35*** 0.36***
(0.13) (0.13) (0.13) (0.13)
Internal Basic Research 0.33*** 0.36*** 0.44***
(0.08) (0.08) (0.09)
Fraction Internal BR with Universities 0.97* 1.02**
(0.52) (0.51)
Internal BR * External BR 0.48**
(0.21)
Time Dummies YES YES YES YES YES
Intercept -2.42 -2.74* -3.62** -4.40*** -4.80***
(1.58) (1.56) (1.55) (1.54) (1.57)
Number of Observations 245 245 245 245 245
Number of Firms 33 33 33 33 33
Wald Chi2 95.53*** 103.27*** 125.36*** 131.26*** 140.20***
Log Likelihood -972.83 -969.94 -964.14 -962.42 -959.90
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Year 
Internal Basic Research (publications) 
External Basic Research (NPRs) 
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Note: Internal and external basic research take values within one standard deviation from the mean. Predictions are 
calculated at the means of the other independent variables.  
 
 
-1 s.d.
+1 s.d.
75
80
86
119
99
176
